Key Drivers
- Strong Liquidity
- Rising Leverage
- Weak Cash Flow
AIAI Summary
TGTX has shifted from a hope-driven story to an execution test on whether BRIUMVI can keep compounding fast enough to justify a rich valuation, but the key watchout is that weak cash conversion and rising debt mean any slowdown in growth could quickly pressure the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Rising Leverage
- •Weak Cash Flow
TGTX shows strong gross profitability and liquidity, but rising leverage, weak cash flow, and a demanding valuation make the equity look financially stretched.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Profit-taking
- •Breakout watch
TGTX remains in a strong uptrend over the last month, but the recent lower highs and lower closes after a peak near $55.83 signal short-term cooling, with $53 and $51.50–$50.30 as key support and a breakout above $55.72–$55.83 needed to resume momentum.
Lower highs and lower closes after the late-June peak suggest short-term cooling and profit-taking
Sentiment & News
Key News Insights:
- •Clinical Progress
- •Sales Momentum
- •Investor Optimism
TG Therapeutics rallied on positive BRIUMVI clinical data and rising sales momentum, with investors now watching whether strong demand can sustain top-line growth.
The news is supportive for the stock, as BRIUMVI's pipeline wins and commercial traction may continue to drive sentiment and valuation higher
Similar Companies in Healthcare
Other companies in the same sector with AI ratings